August 26, 2025 — Leads & Copy — OS Therapies Inc. (NYSE American: OSTX) announced the termination of its Equity Purchase Agreement with Square Gate Capital Master Fund, LLC — Series 3, effective August 26, 2025.
The decision follows a successful warrant exercise inducement and exchange offering that provided the company with $4.2 million in gross proceeds, securing operational funding into mid-year 2026.
According to Paul Romness, MPH, Chairman & CEO of OS Therapies, the company’s projected monthly burn rate is expected to decrease in the latter half of 2025, following the completion of treatment phases in Phase 2b and Phase 1b clinical trials. OS Therapies plans to allocate capital towards securing approval for OST-HER2 in osteosarcoma and analyzing data for OST-504 in prostate cancer.
OS Therapies is a clinical-stage oncology company focused on treatments for Osteosarcoma and other solid tumors. OST-HER2, their lead asset, is an immunotherapy that has received designations from the FDA and European Medicines Agency. The company anticipates submitting a Biologics Licensing Application to the U.S. FDA for OST-HER2 in 2025.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) known as tunable ADC (tADC).
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
stephanie@elev8newmedia.com
